Gendel is an innovative life sciences company formed in December 1998 to develop a drug delivery technology based on red cell sensitisation followed by the application of ultrasound. The company has made outstanding progress in the advancement of this platform technology. Gendel is developing a novel therapy for solid tumours based on the combined application of electro sensitisation and ultrasound (CEFUS) in the absence of drug.